Quick Answer
enGene Therapeutics Inc. reported Total Assets of $221.47 million for fiscal year 2025.
enGene Therapeutics Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $221.47M | -28.8% |
| 2024 | $311.17M | +257.8% |
| 2023 | $86.96M | +263.7% |
| 2022 | $23.91M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $337.11M | +17.9% | +52.2% |
| October 31, 2025 | $221.47M | -28.8% | -9.8% |
| July 31, 2025 | $245.55M | -8.0% | -7.9% |
| April 30, 2025 | $266.65M | -2.5% | -6.7% |
| January 31, 2025 | $285.93M | +206.1% | -8.1% |
| October 31, 2024 | $311.17M | +257.8% | +16.6% |
| July 31, 2024 | $266.88M | — | -2.4% |
| April 30, 2024 | $273.53M | — | +192.8% |
- enGene Therapeutics Inc. showed a decrease of -28.8% in Total Assets compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s total assets has grown by 826.3% (from $23.91 million to $221.47 million).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: